Melphalan 180 mg/m² Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m² or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

Muneer H. Abidi, Rishi Agarwal, Lois Ayash, Abhinav Deol, Zaid Al-Kadhimi, Judith Abrams, Simon Cronin, Marie Ventimiglia, Lawrence Lum, Jeffrey Zonder, Voravit Ratanatharathorn, Joseph Uberti

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Fingerprint Dive into the research topics of 'Melphalan 180 mg/m<sup>2</sup> Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m<sup>2</sup> or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Melphalan 180 mg/m2 Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m2 or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

Medicine & Life Sciences

Melphalan 180 mg/m² Can Be Safely Administered As Conditioning Regimen before an Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma Patients with Creatinine Clearance 60 mL/min/1.73 m² or Lower with Use of Palifermin for Cytoprotection: Results of a Phase I Trial